Suppr超能文献

对淋巴细胞性脉络丛脑膜炎病毒的继发性细胞毒性细胞反应。III. 体外产生的效应细胞的体内保护活性。

Secondary cytotoxic cell response to lymphocytic choriomeningitis virus. III. In vivo protective activity of effector cells generated in vitro.

作者信息

Dunlop M B

出版信息

Immunology. 1978 Feb;34(2):291-302.

Abstract

Secondary cytotoxic T cells were generated by culturing WE3-LCM virus-specific memory CBA/H spleen cells with WE3-LCM virus-infected syngeneic peritoneal cells at 37° for 5 days, and were found to be highly potent in reducing virus titres in the visceral organs of syngeneic recipients when transferred 24 h before intravenous virus challenge (e.g. 3.1×10 cells transferred gave approximately 3 logs reduction of virus titre). Protection was measured by titrating spleens for virus in a plaque assay, usually 2 days post virus-challenge. Intravenously administered secondary effectors did not, however, elicit a reduction in brain virus titres by 3 days after intracerebral inoculation of virus. Cells mediating protection were sensitive to treatment with anti-θ ascitic fluid plus complement. Protection occurred only when donors of secondary cells, infected stimulator cells and recipients shared -2 or -2, and there was a similar genetic restriction for these effectors to efficiently lyse virus-infected targets . Spleen cells from ectromelia virus-memory mice were cultured with ectromelia virus-infected syngeneic peritoneal `stimulator' cells and generated secondary effector cells which protected syngeneic recipients from subsequent challenge with ectromelia but not LCM virus. However, secondary effector cells derived from stimulation of spleen cells from WE3-LCM virus-memory mice with WE3-LCM virus-infected syngeneic stimulator cells caused a significant reduction in spleen virus titres in syngeneic recipients challenged with either ectromelia or LCM virus. If WE3-LCM virus-infected stimulator cells were fixed and responder spleen cells were either from very old (6–12 months post-priming) WE3-LCM virus-memory mice, or from ARM-LCM virus-memory mice, this unidirectional cross-protection of ectromelia virus-challenged mice was less pronounced. One explanation for the unidirectional cross-protection was that the transferred secondary effectors contained and released infectious LCM virus (or defective virions) which adsorbed to recipients' spleen cells; these latter cells displayed both LCM and ectromelia virus-specific antigenic patterns after ectromelia virus challenge, rendering them susceptible to specific T-cell mediated lysis. Clear specificity of effector cells was demonstrated at the effector: target level between LCM virus and ectromelia virus. (Experiments to compare the activity of secondary effectors with primary effector T cells raised or were hampered because of the large amounts of infectious virus in the latter two populations.) Secondary effectors reduced spleen, lung and liver virus titres when transferred 24 h after virus challenge, but were less efficient in protecting recipients than when given before virus.

摘要

通过将WE3-LCM病毒特异性记忆CBA/H脾细胞与经WE3-LCM病毒感染的同基因腹膜细胞在37℃培养5天来产生二级细胞毒性T细胞,并且发现当在静脉内病毒攻击前24小时进行转移时,它在降低同基因受体内脏器官中的病毒滴度方面具有高效力(例如,转移3.1×10个细胞可使病毒滴度降低约3个对数)。通过在噬斑测定中滴定脾脏中的病毒来测量保护作用,通常在病毒攻击后2天进行。然而,静脉内给予的二级效应细胞在脑内接种病毒后3天并没有引起脑内病毒滴度的降低。介导保护作用的细胞对抗θ腹水加补体的处理敏感。只有当二级细胞的供体、感染的刺激细胞和受体具有相同的H-2或H-2时才会出现保护作用,并且这些效应细胞有效裂解病毒感染靶标的过程存在类似的遗传限制。将来自痘苗病毒记忆小鼠的脾细胞与经痘苗病毒感染的同基因腹膜“刺激”细胞一起培养,产生的二级效应细胞可保护同基因受体免受随后的痘苗病毒攻击,但不能保护免受LCM病毒攻击。然而,用经WE3-LCM病毒感染的同基因刺激细胞刺激来自WE3-LCM病毒记忆小鼠的脾细胞所产生的二级效应细胞,可使受到痘苗病毒或LCM病毒攻击的同基因受体的脾脏病毒滴度显著降低。如果将经WE3-LCM病毒感染的刺激细胞固定,而反应性脾细胞来自非常年老(初次免疫后6 - 12个月)的WE3-LCM病毒记忆小鼠或来自ARM-LCM病毒记忆小鼠,那么这种对痘苗病毒攻击小鼠的单向交叉保护作用就不那么明显。对这种单向交叉保护的一种解释是,转移的二级效应细胞含有并释放出感染性LCM病毒(或缺陷病毒粒子),它们吸附到受体的脾细胞上;在痘苗病毒攻击后,这些后者的细胞呈现出LCM病毒和痘苗病毒特异性抗原模式,使其易于受到特异性T细胞介导的裂解。在效应细胞与靶细胞水平上,效应细胞对LCM病毒和痘苗病毒具有明显的特异性。(比较二级效应细胞与一级效应T细胞活性的实验由于后两者群体中存在大量感染性病毒而受到阻碍或无法进行。)在病毒攻击后24小时转移二级效应细胞可降低脾脏、肺和肝脏中的病毒滴度,但与在病毒攻击前给予相比,其保护受体的效率较低。

相似文献

本文引用的文献

5
T-cell-mediated immunopathology in viral infections.病毒感染中的T细胞介导的免疫病理学。
Transplant Rev. 1974;19(0):89-120. doi: 10.1111/j.1600-065x.1974.tb00129.x.
7
Adoptive immunotherapy in malignant disease.恶性疾病中的过继性免疫疗法。
Transplant Rev. 1972;9:54-72. doi: 10.1111/j.1600-065x.1972.tb01561.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验